Large-Scale Analysis Reveals Gene Signature for Survival Prediction in Primary Glioblastoma

Abstract excerpt

Glioblastoma multiforme (GBM) is the most aggressive and common primary central nervous system tumour. Despite extensive therapy, GBM patients usually have poor prognosis with a median survival of 12-15 months. Novel molecular biomarkers that can improve survival prediction and help with treatment strategies are still urgently required. Here we aimed to robustly identify a gene signature panel for improved...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Ferroptosis and cancer prognosis
• Share to Glioma Diagnosis and Treatment
• Share to MicroRNA in disease regulation